Solid Biosciences Eyes FDA Fast-Track Path for Duchenne Gene Therapy, Potential 2027 Filing
Solid Biosciences aims to discuss an accelerated-approval path for its Duchenne gene therapy SGT-003 with the FDA by late 2026, citing safety data from 53 patients and functional data from at least 12. A positive response could support a BLA filing by mid-2027, pending FDA feedback.

